Sarcoidosis is characterized by noncaseating granulomas which form in almost any part of
the body, primarily in the lungs and/or thoracic lymph nodes. Environmental exposures in …

The first classification on this topic categorized cardiomyopathies as heart muscle diseases
with dilated (DCM), hypertrophic, restrictive, arrhythmogenic right ventricular (ARVC), or …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Importance Sarcoidosis is an inflammatory granulomatous disease of unknown cause that
affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any …

Sarcoidosis is a granulomatous disease of unknown cause, occurs worldwide and has a
highly variable prevalence. The disease is typically dominant in the lungs, although it can …

Rationale: There have been no recent comprehensive studies of the epidemiology of
sarcoidosis in the United States. Changes in health care use have made available access to …

This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation
and management of pulmonary sarcoidosis, with each section summarised with key clinical …

Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …

The prevalence of sarcoidosis-related cardiomyopathy is increasing. Sarcoidosis impacts
cardiac function through granulomatous infiltration of the heart, resulting in conduction …

Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array
of immunomodulatory treatment options compared with IPF, due to their inflammatory …